[go: up one dir, main page]

ES2060310T3 - Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion. - Google Patents

Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion.

Info

Publication number
ES2060310T3
ES2060310T3 ES91400163T ES91400163T ES2060310T3 ES 2060310 T3 ES2060310 T3 ES 2060310T3 ES 91400163 T ES91400163 T ES 91400163T ES 91400163 T ES91400163 T ES 91400163T ES 2060310 T3 ES2060310 T3 ES 2060310T3
Authority
ES
Spain
Prior art keywords
phenylalanine
diseases
treatment
miristoilation
miristoil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91400163T
Other languages
English (en)
Inventor
Michel Vincent
Georges Remond
Yolande Herve
Jean-Albert Boutin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADIR SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Application granted granted Critical
Publication of ES2060310T3 publication Critical patent/ES2060310T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A LA UTILIZACION DE LA N-MIRISTOIL-(S)-FENILALANINA EN EL TRATAMIENTO DE LAS ENFERMEDADES COMO EL CANCER O EL SIDA.
ES91400163T 1990-01-25 1991-01-25 Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion. Expired - Lifetime ES2060310T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9000834A FR2657259A1 (fr) 1990-01-25 1990-01-25 Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation.

Publications (1)

Publication Number Publication Date
ES2060310T3 true ES2060310T3 (es) 1994-11-16

Family

ID=9393082

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91400163T Expired - Lifetime ES2060310T3 (es) 1990-01-25 1991-01-25 Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion.

Country Status (14)

Country Link
US (1) US5164414A (es)
EP (1) EP0443891B1 (es)
JP (1) JPH0717503B2 (es)
AT (1) ATE94387T1 (es)
AU (1) AU633395B2 (es)
CA (1) CA2034861A1 (es)
DE (1) DE69100364T2 (es)
DK (1) DK0443891T3 (es)
ES (1) ES2060310T3 (es)
FR (1) FR2657259A1 (es)
IE (1) IE65573B1 (es)
OA (1) OA09478A (es)
PT (1) PT96571A (es)
ZA (1) ZA91574B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672598A1 (fr) * 1991-02-11 1992-08-14 Adir Nouveaux inhibiteurs de n-myristoyltransferase, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5599947A (en) * 1993-01-14 1997-02-04 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US6579891B1 (en) 1995-12-29 2003-06-17 Novactyl, Inc. Agent and method for prevention and treatment of cancer in animals
US6743771B2 (en) 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US6407125B1 (en) 1995-12-29 2002-06-18 Novactyl, Inc. Pharmacological agent and method of treatment
US6127393A (en) * 1995-12-29 2000-10-03 Novactyl, Inc. Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method
US6441009B1 (en) 1998-08-01 2002-08-27 Novactyl, Inc. Agent and method of preventing and treating heavy metal exposure and toxicity
CA2388754C (en) * 1999-10-13 2010-07-13 Marco A. Chacon Therapeutic intervention to mimic the effect of caloric restriction
US6403618B1 (en) 2000-02-15 2002-06-11 Novactyl, Inc. Agent and method for controlling angiogenesis
AU2002318427A1 (en) * 2001-06-25 2003-03-03 University Of Massachusetts N-fatty acid-amino acid conjugates and therapeutic uses
DE10353806A1 (de) * 2003-11-14 2005-07-07 Bundesrepublik Deutschland, vertreten durch das Bundesministerium für Gesundheit, dieses vertreten durch das Robert-Koch-Institut, vertreten durch seinen Präsidenten Verwendung von Aminosäure- und Zucker-Amphiphilen zur Inaktivierung von lipidumhüllten Viren
US7544714B2 (en) * 2004-07-16 2009-06-09 University Of Massachusetts Lipid-amino acid conjugates and methods of use
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
JP6270719B2 (ja) * 2011-07-22 2018-01-31 パシレックス・ファーマシューティカルズ・インコーポレイテッド 合成致死性および癌の治療
JP6320367B2 (ja) 2012-03-30 2018-05-09 ジボダン エス エー 食品フレーバー付与化合物としてのｎ−アシル化メチオニン誘導体
CN104219966B (zh) 2012-03-30 2019-05-28 奇华顿股份有限公司 作为食品加香化合物的n-酰基-氨基酸衍生物
CN104219964B (zh) 2012-03-30 2016-09-21 奇华顿股份有限公司 作为食品加香化合物的n-酰基脯氨酸衍生物
JP6452201B2 (ja) 2012-03-30 2019-01-16 ジボダン エス エー 食品フレーバー付与化合物としてのｎ−アシル−アミノ酸誘導体、それらを含有する粉末組成物
JP6224072B2 (ja) 2012-03-30 2017-11-01 ジボダン エス エー フレーバープロフィール食用組成物の改良のためのｎ−アシル−アミノ酸誘導体
CA2867329C (en) 2012-03-30 2020-03-10 Givaudan S.A. N-acylated 1 - aminocycloalkyl carboxylic acids as food flavouring compounds
BR112014023448B1 (pt) 2012-03-30 2021-06-22 Givaudan Sa Composição comestível ou bebida compreendendo derivados de n-acila de ácido gama amino-butírico e solução padrão
MX369609B (es) * 2012-10-30 2019-11-13 Pacylex Pharmaceuticals Inc Una composición para usarse en el tratamiento de cáncer deficiente en nmt2.
WO2015050535A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
US11122826B2 (en) 2013-10-02 2021-09-21 Givaudan Sa Organic compounds
WO2015050538A1 (en) * 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
WO2015050537A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
EP3057444B1 (en) 2013-10-02 2017-12-06 Givaudan SA Organic compounds having taste-modifying properties
WO2015048990A1 (en) 2013-10-02 2015-04-09 Givaudan Sa Organic compounds having taste-modifying properties
GB201317424D0 (en) 2013-10-02 2013-11-13 Givaudan Sa Improvements in or relating to organic compounds
EP3057448B1 (en) 2013-10-02 2017-12-06 Givaudan S.A. Organic compounds having taste-modifying properties
JP7539760B2 (ja) 2015-07-17 2024-08-26 パシレックス・ファーマシューティカルズ・インコーポレイテッド Ｎｍｔ２の後成的なサイレンシング

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778877A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides II
US4778878A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides I

Also Published As

Publication number Publication date
AU6998791A (en) 1991-08-01
FR2657259B1 (es) 1994-08-19
FR2657259A1 (fr) 1991-07-26
DE69100364T2 (de) 1994-04-21
IE65573B1 (en) 1995-11-01
ZA91574B (en) 1991-11-27
AU633395B2 (en) 1993-01-28
US5164414A (en) 1992-11-17
JPH0717503B2 (ja) 1995-03-01
PT96571A (pt) 1991-10-15
IE910242A1 (en) 1991-07-31
ATE94387T1 (de) 1993-10-15
DK0443891T3 (da) 1993-12-27
DE69100364D1 (de) 1993-10-21
CA2034861A1 (fr) 1991-07-26
EP0443891B1 (fr) 1993-09-15
OA09478A (fr) 1992-11-15
JPH04210916A (ja) 1992-08-03
EP0443891A1 (fr) 1991-08-28

Similar Documents

Publication Publication Date Title
ES2060310T3 (es) Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion.
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
NL300224I1 (nl) 3-Benzazepinzonen gesubstitueerd met een benzocyclobutyl-of indanylalkyla-minoalkylgroep, bruikbaar voor de behandeling van cardiovasculaire aandoeningen.
PT695758E (pt) Amidas e esteres de pentapeptidos inibidores de cancro humano
DE69001117D1 (de) Geraet zur echtzeitlokalisierung der bestrahlungsquelle.
ES2069843T3 (es) Utilizacion de baclofen para la obtencion de medicamentos destinados al tratamiento de la angina de pecho.
ES2153665T3 (es) Usos terapeuticos de productos proteicos bactericidas/incrementadores de la permeabilidad (bpi) para la meningococemia humana.
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
ES2132556T3 (es) Nuevo derivado de benzo-tiadiazina, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen.
ES2128348T3 (es) Obtencion de composiciones para el tratamiento de alteraciones de la proliferacion celular.
FR2651435B1 (es)
ES2041845T3 (es) Empleo de 2-oxo-pirrolidon-1-acetamida para la determinacion de las velocidades glomerulares de filtracion en seres humanos.
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
NO913117L (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
ES499363A0 (es) Procedimiento para la obtencion de derivados de fenilpipera-cina de 1,3,4-oxadiazolilfenoles
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
ES2150418T3 (es) Composiciones farmaceuticas que comprenden calcitonina.
MX9201258A (es) Compuestos para el tratamiento del cancer y procedimiento para su preparacion.
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.
SE8900564D0 (sv) Novel medicinal use
ES2141923T3 (es) Uso hipocolesterolemico, antiaterosclerotico e hipotrigliceridemico de derivados aminoacetilmercapto.
ES1022564Y (es) Armonizador electromagnetico de las alteraciones fisiologicas del cuerpo humano.
YU40098A (sh) Upotreba olanzapina za dobijanje leka
MX9203715A (es) Preparciones para el tratamiento del tejido aloinjertado.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 443891

Country of ref document: ES